Skip to main content
Equibles
SNOA logo

SNOA · Sonoma Pharmaceuticals, Inc.

Track SNOA — free

Use SNOA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.29 +0.00 (+0.00%) At close · Sep 2
Rebalance outlook locked
Market Cap
$6.22M
Shares
4.79M

SNOA metrics

62 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.29
Market cap
$6.22M

Price action

19 metrics
Price change (1W)
-4.4%
Price change (30D)
+15.2%
Price change (3M)
+11.2%
Price change (6M)
-53.1%
Price change (YTD)
-64.6%
Price change (1Y)
-71.0%
Trailing year
Price change (5Y)
—
52-week high
$4.73
52-week low
$1.01
Change from 52-week high
-72.7%
Change from 52-week low
+27.7%
Annualized volatility
74.0%
Beta
1.2
RSI (14D)
50.0
Price vs SMA 50
+4.0%
Price vs SMA 200
-40.9%
Avg volume (3M)
155,946
Relative volume
0.5
Average dollar volume
$194,031

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
4.79M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.3×
reciprocal yield 352.1%
P / book
0.9
reciprocal yield 105.9%
FCF yield
-42.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-36.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
38.9%
Operating margin
-6.4%
Trailing 12 months
Net margin
-10.3%
Gross profit (TTM)
$8.53M
Operating profit (TTM)
−$1.41M
Net income (TTM)
−$2.26M
Trailing 12 months
Diluted EPS (TTM)
$-1.22
FCF margin
-12.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$12.40

Growth

11 metrics
Revenue growth YoY
+59.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$21.92M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+134.4%
Year over year · more shares
Revenue CAGR (3Y)
+13.7%
Revenue CAGR (5Y)
+0.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-34.3%
Return on assets
-12.5%
Debt / equity
—
Current ratio
3.0
EBITDA (TTM)
−$1.27M
Free cash flow (TTM)
−$2.65M
Quick ratio
2.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$5.34M
Total assets
$18.11M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.57M
Capital expenditures (TTM)
$88,000
R&D (TTM)
$2.27M
SG&A (TTM)
$7.66M
Stock compensation (TTM)
$256,000
R&D / revenue
10.4%
Stock compensation / revenue
1.2%

Ownership (13F)

3 metrics
13F filers
14
13F filer change QoQ
-3
Institutional ownership
2.3%

Short interest

3 metrics
Short interest
4.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1367083 CUSIP 83558L303 13F (30d) 12 filings 12 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)